/
Oncology
Advanced Malignant Solid Tumors
39
Pipeline Programs↗
39
Active Trials↗
43
Companies Involved↗
Advanced Malignant Solid Tumors is a moderately active landscape with 39 programs across 43 companies. The most active players are Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Qilu Pharmaceutical Co., Ltd., Tasly Biopharmaceuticals Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
JPhase 1
Phase 2TPhase 2CPhase 2CPhase 1SPhase 1
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
2 programs
Qilu Pharmaceutical Co., Ltd.
1 program
Tasly Biopharmaceuticals Co., Ltd.
1 program
CSPC Megalith Biopharmaceutical Co.,Ltd.
1 program
Chongqing Precision Biotech Co., Ltd
1 program
Shanghai Juncell Therapeutics
1 program
Pipeline
Programs by Phase
Preclinical11
Phase 114
Phase 214
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
33programs
Small molecule1958%
Cell therapy721%
Monoclonal antibody515%
Vaccine26%
Modality classified for 90% of 39 pipeline programs.
Analysis
Trial Status
93
clinical trials
Recruiting28 · 30%
Completed22 · 24%
Unknown status21 · 23%
Terminated10 · 11%
Not yet recruiting8 · 9%
Active, not recruiting3 · 3%
Other1 · 1%
Clinical Trials
Trial Activity
93 trials
A Single-arm, Open-label, Single/Multiple-dose Escalation, and Cohort Expansion Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Oral CSCJC3456 Tablets in Patients With Advanced Malignant Solid Tumors
Recruiting·CChangshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.·Phase 1·NCT06717750·102 enrolled
A Single-Arm, Open-Label, Dose-Escalation/Cohort-Expansion Phase Ia/Ib Study to Evaluate Safety, Tolerability, PK/PD Profiles, and Preliminary Efficacy of TPD3310 Injection in Advanced Malignant Solid Tumor Patients
Recruiting·TTAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.·Phase 1·NCT07368127·112 enrolled
a Polyphenol Whole Tumor Cell Vaccine in Patients With Advanced Malignant Solid Tumors
Recruiting·—·Phase 1·NCT06878612·9 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)